Biopharmaceutical company Alkermes plc (ALKS) announced Friday the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee.
Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. Most recently, he served as CFO of Omega Therapeutics, a then publicly-traded biotechnology company.
Prior to that, Reed was the CFO at Aldeyra Therapeutics. Earlier in his career, Reed spent more than a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the U.S. and Puerto Rico.
Reed's experience also includes roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank. He currently serves on the board of directors of Scholar Rock Holding Corp., a publicly-traded biotechnology company.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.